What is semaglutide and why has it changed weight management?
Semaglutide is an FDA-approved GLP-1 (glucagon-like peptide-1) receptor agonist that has demonstrated unprecedented efficacy for weight management, producing average weight loss of 15-17% of body weight in clinical trials (1). It is sold under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management).
Unlike most peptides discussed on this site, semaglutide is a fully regulated pharmaceutical with extensive clinical trial data involving tens of thousands of participants. It was originally developed for type 2 diabetes management and later received FDA approval specifically for chronic weight management in 2021.
Semaglutide represents a shift in how medicine approaches obesity, treating it as a chronic metabolic condition rather than a behavioral issue. Its success has spawned a new class of weight management medications and generated significant public interest.
How does semaglutide work?
Semaglutide mimics the natural hormone GLP-1, reducing appetite by acting on brain centers that control hunger and satiety, while also slowing gastric emptying to increase feelings of fullness.
The GLP-1 system
GLP-1 is an incretin hormone naturally released by the gut after eating. It has three primary effects:
- Appetite suppression: GLP-1 acts on receptors in the hypothalamus to reduce hunger signals
- Gastric slowing: It delays gastric emptying, helping you feel fuller for longer after meals
- Insulin regulation: GLP-1 stimulates glucose-dependent insulin secretion and suppresses glucagon
Natural GLP-1 is rapidly degraded by the enzyme DPP-4 and has a half-life of only 2-3 minutes. Semaglutide has been engineered with specific amino acid modifications and a fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing (1).
Brain effects on food reward
Research shows semaglutide reduces activity in brain regions associated with food reward and craving. Neuroimaging studies demonstrate decreased activation in the insula and putamen when patients on semaglutide view food images, suggesting the medication fundamentally changes how the brain responds to food cues.
Clinical trial results
The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the largest clinical evidence base for any weight loss medication, demonstrating consistent and clinically meaningful weight loss across diverse populations.
STEP 1: Primary weight loss trial
In the landmark STEP 1 trial involving 1,961 adults with obesity or overweight with at least one weight-related comorbidity:
- Average weight loss: 14.9% of body weight over 68 weeks (vs. 2.4% for placebo)
- 86.4% of participants lost at least 5% of body weight
- 69.1% lost at least 10% of body weight
- 50.5% lost at least 15% of body weight (1)
STEP 2: Patients with type 2 diabetes
The STEP 2 trial showed semaglutide 2.4 mg produced 9.6% weight loss in patients with type 2 diabetes over 68 weeks, along with improved glycemic control (2).
STEP 4: Maintenance study
STEP 4 examined what happens when semaglutide is withdrawn. Participants who continued semaglutide maintained their weight loss, while those switched to placebo regained approximately two-thirds of their lost weight over 48 weeks (3). This finding underscores that semaglutide may need to be used long-term for sustained results.
Dosing and administration
Semaglutide for weight management (Wegovy) is administered as a once-weekly subcutaneous injection with a gradual dose escalation schedule.
| Week | Dose |
|---|---|
| Weeks 1-4 | 0.25 mg |
| Weeks 5-8 | 0.5 mg |
| Weeks 9-12 | 1.0 mg |
| Weeks 13-16 | 1.7 mg |
| Week 17+ | 2.4 mg (maintenance) |
The gradual escalation is designed to minimize gastrointestinal side effects. Semaglutide is injected into the abdomen, thigh, or upper arm using a prefilled pen device. It can be administered at any time of day, with or without meals.
Side effects and safety
Gastrointestinal side effects are the most common concern with semaglutide, affecting approximately 40-50% of users, though most are mild to moderate and improve over time.
Common side effects
- Nausea (44% in STEP 1)
- Diarrhea (30%)
- Vomiting (24%)
- Constipation (24%)
- Abdominal pain (20%)
Serious but rare risks
- Pancreatitis: Rare cases have been reported. Patients with a history of pancreatitis should discuss risk with their physician.
- Gallbladder disease: Rapid weight loss can increase gallstone risk. Studies show higher rates of gallbladder-related events in semaglutide users.
- Thyroid C-cell tumors: Animal studies showed increased thyroid tumor risk. Semaglutide carries a boxed warning and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- Muscle mass loss: Some research indicates a portion of weight lost may come from lean body mass. Resistance training and adequate protein intake are recommended.
Key takeaways
- Semaglutide is an FDA-approved GLP-1 medication with the strongest clinical evidence for pharmacological weight loss
- Average weight loss of 15-17% of body weight in clinical trials over 68 weeks
- It works by reducing appetite and slowing gastric emptying via GLP-1 receptor activation
- Gastrointestinal side effects are common but usually improve with gradual dose escalation
- Weight regain is likely if the medication is discontinued
- Semaglutide requires a prescription and should be used under medical supervision
- Lifestyle modifications including diet and exercise remain important alongside medication